Skip to main content
Clinical Trials/JPRN-UMIN000023145
JPRN-UMIN000023145
Completed
Phase 1

Examination of the effectiveness and safety of multidisciplinary therapy with docetaxel for high-risk prostate cancer - Multidisciplinary therapy with docetaxel for high-risk prostate cancer

Juntendo University Hospital0 sites100 target enrollmentSeptember 1, 2016
Conditionsprostate cancer

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
prostate cancer
Sponsor
Juntendo University Hospital
Enrollment
100
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 1, 2016
End Date
August 31, 2023
Last Updated
2 years ago
Study Type
Interventional
Sex
Male

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\.Males under the age of 20\. 2\. Refuses to give informed consent. 3\. Refuses or is unable to have pelvic MRI or CT scan. 4\. Without criteria for administration of docetaxel. 5\. Deemed higher risk of administration of docetaxel by urologists or other physicians.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Evaluation of the safety and effectiveness of the MID-C/ApiFix system in adolescent idiopathic scoliosis.Spinal curvature1002837710005944
NL-OMON43676Vrije Universiteit Medisch Centrum33
Active, not recruiting
Not Applicable
Safety and effectiveness clinical evaluation of the range of injectable medical devices HYDRAGEL C in facial aesthetic treatmentSubjects across groups present with moderate to severe facial aesthetic concerns, including peri-oral lines, nasolabial folds, lip volume deficits, and cheeks/cheekbones volume deficit, as gauged by various dermatological scalesSkin and Connective Tissue Diseases
ISRCTN13586698ouna Aesthetics75
Active, not recruiting
Not Applicable
Clinical study to evaluate the safety and effectiveness of the use of two hyaluronic acid injectable products (Perfectha® Derm Lidocaine and Perfectha® Deep Lidocaine) in the treatment of lipsFor Perfectha® Derm Lidocaine: very thin to thin lip volume and with lip contour somewhat well-defined to poorly definedfor Perfectha® Deep Lidocaine: thin to moderate lip volumeNot Applicable
ISRCTN72858148Sinclair Pharma68
Not yet recruiting
Phase 4
euroEPO in mild-moderate Alzheimer's disease amnesic variantmild-moderate Alzheimer's diseaseAlzheimer DiseaseDementiaBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental Disorders
RPCEC00000410Center of Molecular Immunology (CIM)1,456
Recruiting
Phase 1
Investigating the endolift method in the treatment of primary axillary hyperhidrosis
IRCT20200127046282N43Tehran University of Medical Sciences10